Effects of the use of silver-coated urinary catheters on the incidence of catheter-associated bacteriuria and urinary tract infection in dogs.

OBJECTIVE To determine the effects of silver-coated versus standard silicone urinary catheters on the incidence of catheter-associated bacteriuria (CAB) and catheter-associated urinary tract infection (CAUTI) in dogs. DESIGN Randomized controlled clinical trial. ANIMALS 36 dogs requiring urinary bladder catheterization for ≥ 24 hours. PROCEDURES Dogs were randomly assigned to receive a silver-coated or non-silver-coated (control) silicone Foley catheter. Urine samples for cytologic examination and bacterial culture were collected at the time of catheter insertion and daily until catheters were removed (≥ 24 hours to 7 days later). Results were compared between groups. RESULTS No significant differences were identified between catheter groups in the incidence of CAB or CAUTI. Although the median time to development of cytologically detected bacteriuria, culture-detected bacteriuria, and CAUTI did not differ significantly between groups, median time to CAB development (either method) was significantly longer for dogs that received a control catheter rather than a silver-coated catheter. For both types of catheters combined, older age was a significant predictor of culture-detected bacteriuria, and longer duration of catheterization was a significant predictor of culture-detected bacteriuria and overall CAB. CONCLUSIONS AND CLINICAL RELEVANCE Silver-coated urinary catheters provided no clinical benefit over standard urinary catheters for the dogs of this study and were associated with earlier development of CAB but not CAUTI. A larger prospective study is required to definitively determine whether the use of silver-coated urinary catheters should or should not be considered to reduce the risk of CAB or CAUTI in dogs.

Lack of neuroprotection of inhibitory peptides targeting Jun/JNK after transient focal cerebral ischemia in spontaneously hypertensive rats.

In this study, we have assessed the ability of two TAT-fused peptides PYC36D-TAT and JNKI-1D-TAT (JNKI-1 or XG-102), which respectively inhibit jun proto-oncogene (c-Jun) and c-Jun N-terminal kinase (JNK) activation, to reduce infarct volume and improve functional outcome (adhesive tape removal) after transient focal cerebral ischemia in Spontaneously Hypertensive (SH) rats. PYC36D-TAT and JNKI-1D-TAT peptide batches used for experiments were tested in vitro and protected cortical neurons against glutamate excitotoxicity. Rats were treated intravenously with three different doses of PYC36D-TAT (7.7, 76, or 255 nmol/kg), JNKI-1D-TAT (255 nmol/kg), D-TAT peptide (255 nmol/kg), or saline (vehicle control), 10 minutes after reperfusion after 90 minutes of middle cerebral artery occlusion (MCAO). Contrary to other stroke models, no treatment significantly reduced infarct volume or improved functional score measurements compared with vehicle-treated animals when assessed 48 hours after MCAO. Additionally, assessment of the JNKI-1D-TAT peptide, when administered 1 or 2 hours after reperfusion after 90 minutes of MCAO, also did not improve histological or functional outcomes at 48 hours after occlusion. This study is the first to evaluate the efficacy of PYC36D-TAT and JNKI-1D-TAT using the SH rat, which has recently been shown to be more sensitive to AMPA receptor activation rather than to NMDA receptor activation after cerebral ischemia, and which may have contributed to the negative findings.